Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 18/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17602132 | 1.00 | KDM4C (0.68) | KDM4C | |
| SCHEMBL29542558 | 0.95 | KDM4C (0.69) | KDM4C | |
| SCHEMBL17602194 | 0.95 | KDM4C (0.69) | KDM4C | |
| SCHEMBL17623926 | 0.94 | KDM4C (0.66) | KDM4C | |
| SCHEMBL17615753 | 0.85 | KDM4C (0.51) | KDM4C | |
| SCHEMBL17898300 | 0.81 | KDM4C (0.45) | KDM4C | |
| SCHEMBL17898296 | 0.81 | KDM4C (0.44) | KDM4C | |
| SCHEMBL17898302 | 0.80 | KDM4C (0.44) | KDM4C | |
| SCHEMBL17602134 | 0.80 | KDM4C (0.44) | KDM4C | |
| SCHEMBL17898301 | 0.79 | KDM4C (0.45) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066355-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12172998-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11535616-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2022-12-27 | — | — | US | disclosed |
| EP-3430008-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172998-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | KDM4C 9/4885 |
| US-11535616-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | KDM4C 9/4885 |
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885 |
| US-20250066355-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.